CLOV Quote, Financials, Valuation and Earnings

The Cigna Group has a net margin of -4.91% compared to Clover Health Investments Corp.'s net margin of 2.83%. Clover Health Investments Corp.'s return on equity of -16.93% beat The Cigna Group's return on equity of 15.87%.

Clover Health Investments Corp. has a consensus price target of $3.23, signalling upside risk potential of 21.55%. On the other hand The Cigna Group has an analysts' consensus of $328.74 which suggests that it could grow by 22.47%. Given that The Cigna Group has higher upside potential than Clover Health Investments Corp., analysts believe The Cigna Group is more attractive than Clover Health Investments Corp..

Clover Health Investments Corp. has a beta of 2.243, which suggesting that the stock is 124.341% more volatile than S&P 500. In comparison The Cigna Group has a beta of 0.257, suggesting its less volatile than the S&P 500 by 74.285%.

Clover Health Investments Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Cigna Group offers a yield of 2.25% to investors and pays a quarterly dividend of $1.51 per share. Clover Health Investments Corp. pays -- of its earnings as a dividend. The Cigna Group pays out 46.19% of its earnings as a dividend. The Cigna Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Clover Health Investments Corp. quarterly revenues are $496.7M, which are smaller than The Cigna Group quarterly revenues of $69.8B. Clover Health Investments Corp.'s net income of -$24.4M is lower than The Cigna Group's net income of $2B. Notably, Clover Health Investments Corp.'s price-to-earnings ratio is -- while The Cigna Group's PE ratio is 11.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clover Health Investments Corp. is 0.75x versus 0.27x for The Cigna Group. Usually stocks with elevated PS ratios are considered overvalued.

NeueHealth, Inc. has a net margin of -4.91% compared to Clover Health Investments Corp.'s net margin of 3.27%. Clover Health Investments Corp.'s return on equity of -16.93% beat NeueHealth, Inc.'s return on equity of -3241.93%.

Clover Health Investments Corp. has a consensus price target of $3.23, signalling upside risk potential of 21.55%. On the other hand NeueHealth, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3.66%. Given that Clover Health Investments Corp. has higher upside potential than NeueHealth, Inc., analysts believe Clover Health Investments Corp. is more attractive than NeueHealth, Inc..

Clover Health Investments Corp. has a beta of 2.243, which suggesting that the stock is 124.341% more volatile than S&P 500. In comparison NeueHealth, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Clover Health Investments Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeueHealth, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clover Health Investments Corp. pays -- of its earnings as a dividend. NeueHealth, Inc. pays out -- of its earnings as a dividend.

Clover Health Investments Corp. quarterly revenues are $496.7M, which are larger than NeueHealth, Inc. quarterly revenues of $209.1M. Clover Health Investments Corp.'s net income of -$24.4M is lower than NeueHealth, Inc.'s net income of $6.8M. Notably, Clover Health Investments Corp.'s price-to-earnings ratio is -- while NeueHealth, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clover Health Investments Corp. is 0.75x versus 0.06x for NeueHealth, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Oscar Health, Inc. has a net margin of -4.91% compared to Clover Health Investments Corp.'s net margin of -4.6%. Clover Health Investments Corp.'s return on equity of -16.93% beat Oscar Health, Inc.'s return on equity of -21.36%.

Clover Health Investments Corp. has a consensus price target of $3.23, signalling upside risk potential of 21.55%. On the other hand Oscar Health, Inc. has an analysts' consensus of $14.38 which suggests that it could fall by -15.94%. Given that Clover Health Investments Corp. has higher upside potential than Oscar Health, Inc., analysts believe Clover Health Investments Corp. is more attractive than Oscar Health, Inc..

Clover Health Investments Corp. has a beta of 2.243, which suggesting that the stock is 124.341% more volatile than S&P 500. In comparison Oscar Health, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Clover Health Investments Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oscar Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clover Health Investments Corp. pays -- of its earnings as a dividend. Oscar Health, Inc. pays out -- of its earnings as a dividend.

Clover Health Investments Corp. quarterly revenues are $496.7M, which are smaller than Oscar Health, Inc. quarterly revenues of $3B. Clover Health Investments Corp.'s net income of -$24.4M is higher than Oscar Health, Inc.'s net income of -$137.5M. Notably, Clover Health Investments Corp.'s price-to-earnings ratio is -- while Oscar Health, Inc.'s PE ratio is 51.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clover Health Investments Corp. is 0.75x versus 0.40x for Oscar Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Progyny, Inc. has a net margin of -4.91% compared to Clover Health Investments Corp.'s net margin of 4.43%. Clover Health Investments Corp.'s return on equity of -16.93% beat Progyny, Inc.'s return on equity of 11.79%.

Clover Health Investments Corp. has a consensus price target of $3.23, signalling upside risk potential of 21.55%. On the other hand Progyny, Inc. has an analysts' consensus of $29.11 which suggests that it could grow by 18.58%. Given that Clover Health Investments Corp. has higher upside potential than Progyny, Inc., analysts believe Clover Health Investments Corp. is more attractive than Progyny, Inc..

Clover Health Investments Corp. has a beta of 2.243, which suggesting that the stock is 124.341% more volatile than S&P 500. In comparison Progyny, Inc. has a beta of 0.969, suggesting its less volatile than the S&P 500 by 3.145%.

Clover Health Investments Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Progyny, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clover Health Investments Corp. pays -- of its earnings as a dividend. Progyny, Inc. pays out -- of its earnings as a dividend.

Clover Health Investments Corp. quarterly revenues are $496.7M, which are larger than Progyny, Inc. quarterly revenues of $313.3M. Clover Health Investments Corp.'s net income of -$24.4M is lower than Progyny, Inc.'s net income of $13.9M. Notably, Clover Health Investments Corp.'s price-to-earnings ratio is -- while Progyny, Inc.'s PE ratio is 38.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clover Health Investments Corp. is 0.75x versus 1.73x for Progyny, Inc.. Usually stocks with elevated PS ratios are considered overvalued.